^
    Back
    Association details:
    Biomarker:GSDMB expression
    Cancer:Bladder Cancer
    Drug:Focus V (anlotinib) (Multi-tyrosine kinase inhibitor)
    Direction:Sensitive
    Evidence:
    Evidence Level:
    Sensitive: D – Preclinical
    Source:
    Pharmgenomics Pers Med
    Title:

    Anlotinib Enhances the Therapeutic Effect of Bladder Cancer with GSDMB Expression: Analyzed from TCGA Bladder Cancer Database & Mouse Bladder Cancer Cell Line

    Published date:
    03/17/2023
    Excerpt:
    In vivo experiments showed that Anlotinib was more effective in the treatment of GSDMB-positive bladder cancer than GSDMB-negative bladder cancer.
    DOI:
    10.2147/PGPM.S398451